While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Merck reported adjusted earnings of $1.72 per ... charge of 23 cents related to M&A deals with LaNova Medicines and Hansoh Pharma. Revenues rose 7% year over year (9% excluding Fx) to $15.62 ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Merck is one of the largest pharmaceutical ... HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the development of LM-299, a potential cancer ...